指南推荐的COPD吸入方案与死亡率、急性加重及生活质量的相关性:长期氧疗试验的二次分析
本研究对长期氧疗试验(LOTT)中738例伴中度低氧血症的COPD患者进行二次分析,按2017 GOLD策略将吸入方案分为符合、治疗不足或可能过度治疗。中位随访2.3年,符合推荐与治疗不足组在复合结局或死亡时间上无差异;低风险患者中可能过度治疗与更高急性加重风险相关(HR 1.42,95%CI 1.09-1.87),吸入糖皮质激素与肺炎风险增加64%相关(IRR 1.64,95%CI 1.01-2.66)。
要点
- 符合2017 GOLD推荐的吸入方案与治疗不足相比,未改善死亡或住院复合结局。
- 低风险患者中可能过度治疗与急性加重风险升高相关(HR 1.42)。
- 吸入糖皮质激素治疗与肺炎风险增加64%相关(IRR 1.64)。
核心结论
- 在中度低氧血症COPD患者中,符合2017 GOLD策略的吸入方案与治疗不足相比,临床结局无差异。
- 低风险患者中可能过度治疗与急性加重风险升高相关,吸入糖皮质激素与肺炎风险增加相关。
- 结果提示需重新评估基于风险分层模型的吸入治疗策略的有效性。
研究设计与样本
- 研究类型:长期氧疗试验(LOTT)的二次分析。
- 研究对象:2009至2015年入组、伴中度静息或运动性低氧血症的COPD患者738例(73.4%男性,平均年龄68.8岁)。
- 暴露定义:入组时患者报告的吸入方案,按2017 GOLD策略分为符合、治疗不足或可能过度治疗。
- 主要复合结局:至死亡或首次COPD住院的时间。
- 统计方法:多变量Cox比例风险模型,按GOLD预测急性加重风险分层(高 vs 低),按中心聚类并校正潜在混杂因素。
主要发现
- 571例(77.4%)为未来急性加重低风险;233例(31.6%)报告符合GOLD推荐的方案;54.1%的方案可能过度治疗。
- 中位随访2.3年期间,332例(44.9%)发生复合结局。
- 符合推荐与治疗不足组在复合结局或死亡时间上无差异。
- 低风险患者中,可能过度治疗与急性加重风险升高相关(HR 1.42;95%CI 1.09-1.87)。
- 吸入糖皮质激素治疗与肺炎风险增加64%相关(IRR 1.64;95%CI 1.01-2.66)。
关键数值与推荐
- GOLD 2017策略用于将吸入方案分类为符合、治疗不足或可能过度治疗。
- 低风险患者中可能过度治疗与急性加重风险相关(HR 1.42;95%CI 1.09-1.87)。
- 吸入糖皮质激素与肺炎风险相关(IRR 1.64;95%CI 1.01-2.66)。
临床怎么用
- 对伴中度低氧血症的COPD患者,按2017 GOLD风险分层选择吸入方案未显示优于治疗不足。
- 低风险患者应避免不必要的过度治疗,尤其是吸入糖皮质激素,以降低急性加重和肺炎风险。
- 临床需重新审视基于风险分层模型的吸入治疗策略的有效性。
局限性
- 本研究为LOTT试验的二次分析,结果可能受原始研究人群选择影响。
- 吸入方案为患者报告,可能存在分类偏倚。
- 研究仅纳入伴中度低氧血症的COPD患者,结论外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Although inhaled therapy reduces exacerbations among patients with COPD, the effectiveness of providing inhaled treatment per risk stratification models remains unclear. RESEARCH QUESTION: Are inhaled regimens that align with the 2017 Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy associated with clinically important outcomes? STUDY DESIGN AND METHODS: We conducted secondary analyses of Long-term Oxygen Treatment Trial (LOTT) data. The trial enrolled patients with COPD with moderate resting or exertional hypoxemia between 2009 and 2015. Our exposure was the patient-reported inhaled regimen at enrollment, categorized as either aligning with, undertreating, or potentially overtreating per the 2017 GOLD strategy. Our primary composite outcome was time to death or first hospitalization for COPD. Additional outcomes included individual components of the composite outcome and time to first exacerbation. We generated multivariable Cox proportional hazard models across strata of GOLD-predicted exacerbation risk (high vs low) to estimate between-group hazard ratios for time to event outcomes. We adjusted models a priori for potential confounders, clustered by site. RESULTS: The trial enrolled 738 patients (73.4% men; mean age, 68.8 years). Of the patients, 571 (77.4%) were low risk for future exacerbations. Of the patients, 233 (31.6%) reported regimens aligning with GOLD recommendations; most regimens (54.1%) potentially overtreated. During a 2.3-year median follow-up, 332 patients (44.9%) experienced the composite outcome. We found no difference in time to composite outcome or death among patients reporting regimens aligning with recommendations compared with undertreated patients. Among patients at low risk, potential overtreatment was associated with higher exacerbation risk (hazard ratio, 1.42; 95% CI, 1.09-1.87), whereas inhaled corticosteroid treatment was associated with 64% higher risk of pneumonia (incidence rate ratio, 1.64; 95% CI, 1.01-2.66). INTERPRETATION: Among patients with COPD with moderate hypoxemia, we found no difference in clinical outcomes between inhaled regimens aligning with the 2017 GOLD strategy compared with those that were undertreated. These findings suggest the need to reevaluate the effectiveness of risk stratification model-based inhaled treatment strategies.
引用
- Keller T, Spece LJ, Donovan LM, et al. Association of Guideline-Recommended COPD Inhaler Regimens With Mortality, Respiratory Exacerbations, and Quality of Life: A Secondary Analysis of the Long-Term Oxygen Treatment Trial. Chest. 2020. PMID: 32278779. doi:10.1016/j.chest.2020.02.073
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。